Piper Sandler Reiterates Overweight Rating on BioMarin Pharmaceutical Inc. (BMRN), 'anticipate the stock will be up meaningfully on the open tomorrow'
Tweet Send to a Friend
Piper Sandler analyst Christopher Raymond reiterated an Overweight rating and $128.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
